DIAGNOSTIC TECHNIQUE FOR BLADDER CANCER BY CANCER-SPECIFIC MARKER TEDP1 (VERSIONS) AND KIT FOR IMPLEMENTING IT Russian patent published in 2012 - IPC C12Q1/68 C12N15/10 G01N33/53 

FIELD: medicine.

SUBSTANCE: biomaterial preparation is RNA recovery, cDNA synthesis on the RNA matrix, control of the TFDP1 cDNA concentration by a control gene, quantitative PCR-amplification of a TFDP1 gene fragment. These procedures are followed by evaluation of the amplified TFDP1 DNA fragment for a biomaterial sample. If the TFDP1 gene cDNA concentration in physiological fluids exceeds 1.5% of the ACTB beta-actin gene cDNA concentration, the presence of transitional cell bladder cancer is diagnosed. A kit for implementing the CR-based technique includes two primers with a certain sequence at molar ratio 1:1. A version technique provides the ELISA-based diagnosing. Patient's urine and blood are sampled to recover a mixture of protein components of urine and blood that is followed by ELISA with monoclonal antibodies and/or polyclonal antibodies and/or their fragments to TFDP1 recombinant protein and/or its unique fragments more than 8 amino acids long. Bladder cancer is diagnosed if observing the TFDP1 protein concentration in the analysed samples exceeding the 5-fold TFDP1 protein concentration in the reference.

EFFECT: technique enables high-reliability diagnosing of bladder cancer, including at the early stage of progressing neoplastic aberration.

3 cl, 4 tbl, 4 dwg